Hasil Pencarian  ::  Simpan CSV :: Kembali

"ABSTRAKLatar Belakang: Dalam beberapa dekade terakhir telah dikembangkan terapi paliatif yang bertujuan untuk mengeliminasi metastasis. Kemoterapi paliatif banyak dipilih menjadi terapi standar pada tatalaksana kanker kolorektal stadium lanjut. Pemberian 5-fluorouracil 5-FU intravena ditambah dengan leucovorin LV dan targeted therapy bevacizumab telah menjadi terapi paliatif standar dalam beberapa tahun terakhir. Di Indonesia, belum ada penelitian yang membandingkan efektifitas pemberian regimen kemoterapi Bevacizumab mFOLFOX6 dan Bevacizumab XELOX. Metode: Penelitian ini menggunakan desain potong lintang pada 15 pasien karsinoma kolorektal dengan metastasis hati dengan 11 pasien menjalani protokol Bevacizumab mFOLFOX6 dan 4 pasien menjalani protokol Bevacizumab XELOX. Efektifitas respons dilihat dengan menggunakan kadar CEA dan hasil CT scan. Hasil: Dengan menggunakan protokol kemoterapi Bevacizumab mFOLFOX6 81,8 subjek memberikan respons stable disease dan 54,5 subjek memberikan respons progressive disease. Sementara itu, dengan menggunakan protokol kemoterapi Bevacizumab XELOX 75,0 subjek memberikan respons stable disease dan 50,0 subjek memberikan respons partial response. Efektivitas kemoterapi tidak memiliki hubungan yang bermakna dengan regimen/protokol kemoterapi yang digunakan Bevacizumab mFOLFOX6 dan Bevacizumab XELOX, baik berdasarkan respon CT Scan p = 0,993 maupun kadar CEA 0,774 . Tidak terdapat pula hubungan antara variabel faktor dengan efektivitas kemoterapi. Kesimpulan: Efektivitas kemoterapi tidak memiliki hubungan yang bermakna dengan regimen/protokol kemoterapi yang digunakan. Selain itu, variabel usia, jenis kelamin, IMT, SGA, skor Karnofsky, lokasi tumor primer, jenis operasi, waktu kemoterapi dan tipe histopatologi tidak memiliki hubungan yang bermakna dengan efektivitas kemoterapi.

---

ABSTRACTBackground In the last few decades, palliative therapy has been developed to eliminate metastasis. Palliative chemotherapy has become a standard therapy in the treatment of late stage colorectal cancer. Treatment with 5 fluorouracil 5 FU plus leucovorin intravenous LV and targeted therapies bevacizumab has become a standard palliative therapy in recent years. In Indonesia, there were no study comparing the effectiveness of Bevacizumab mFOLFOX6 and Bevacizumab XELOX chemotherapy regimens. Method This study used a cross sectional design in 15 patients with liver metastatic colorectal carcinoma which 11 patients were treated with Bevacizumab mFOLFOX6 protocol and 4 patients were treated with Bevacizumab XELOX protocol. The effectiveness of the response were measured using CEA concentration and CT scan result. Results With the Bevacizumab mFOLFOX6 protocol 81.8 of the subjects responded as stable disease and 54.5 responded as progressive disease. Meanwhile, with the Bevacizumab XELOX protocols 75.0 of the subjects responded as stable disease and 50.0 responded as partial response. Effectiveness of chemotherapy did not have a relationship with the chemotherapy protocols used Bevacizumab mFOLFOX6 and XELOX , based on CT scans p 0.993 and CEA levels 0.774 . In addition, there is no relationship between variable factors and the effectiveness of chemotherapy. Conclusions Effectiveness of chemotherapy did not have a relationship with the chemotherapy protocols used. In addition, the variables of age, sex, BMI, SGA, score Karnofsky, primary tumor site, type of surgery, chemotherapy and histopathology type of time did not have a relationship with the effectiveness of chemotherapy. "

"ABSTRAKLatar belakang: Tumor periampula merupakan jenis kanker dengan tingkat mortalitas yang tinggi dan sebagian besar dating dengan stadium lanjut. Terdapat terapi operasi paliatif double-bypass untuk pasien tumor periampula unresectable untuk memperbaiki kualitas hidup.Metode: Studi kohort retrospektif dengan data diambil melalui rekam medis pada pasien periampula yang dilakukan tindakan double-bypass dari periode Januari 2010 – Agustus 2015. Tingkat kesintasan dinilai menggunakan metode Kaplan-Meier dan kualitas hidup pada pasien yang masih hidup dinilai menggunakan kuisioner EORTC QLQ-C30.Hasil: 31 pasien tumor periampuladan diketahui 25 kasus (80%) diantaranya unresectable sehingga dilakukan operasi paliatif double-bypass, jenis tumor periampula pada subjek penelitian yaitu tumor kaput pancreas 68%, ampula vater 16%, duodenum 12%, dan kolangiokarsinoma 4%. Median waktu kesintasan sebesar 3 bulan (95%CI 2,13 – 3,87). Kualitas hidup subjek secara keseluruhan baik, dengan skor status kesehatan umum 60, rerata skor skala fungsional 82,36 (SB 4,9), dan rerata skor gejala yang mempengaruhi kualitas hidup 18,36 (SB 7,48).

---

ABSTRACTBackground: Periampullary tumor is a type of cancer with high mortality rate and most patients present in advanced stage. There is palliative double bypass surgery for patients with unresectable periampullary tumors to improve the quality of life.Method: This study aims to determine the survival rate of patients with unresectable periampullary tumors who underwent palliative double bypass surgery. The survival rate is assessed using Kaplan- Meier method and quality of live in patients whom survive were assessed using EORTC QLQ-C30 questionnaire.Results: In January 2010 - August 2015, we retrospectively analyzed 31 patients with tumors known periampullary and 25 cases (80%) of whom are unresectable so palliative double bypass surgery. Types of periampullary tumors on the subject of this study are pancreatic head tumors (68%), papilla Vater (12%), duodenum (12%), ampulla Vater (4%), and cholangiocarcinoma (4%). Median survival time was 3 months (95% CI 2.13 to 3.87). Quality of life of the subjects are good, with general health status scores’ are 60, mean functional scale scores are 82.36 (SB 4.90), and mean scores of symptoms that affect quality of life are 18,36 (SB 7.48).Conclusion: Palliative double bypass surgery may be an option to improve quality of life of patients with unresectable periampullary tumors.;;"